Abstract
We present the first direct comparative evaluation of an antibody-drug conjugate and of a small molecule-drug conjugate for cancer therapy, using chemically defined products which bind with high-affinity to carbonic anhydrase IX, a marker of tumor hypoxia and of renal cell carcinoma.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / pharmacology*
-
Antigens, Neoplasm / metabolism
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Carbonic Anhydrase IX / antagonists & inhibitors
-
Carbonic Anhydrase IX / metabolism
-
Carbonic Anhydrase Inhibitors / chemical synthesis
-
Carbonic Anhydrase Inhibitors / chemistry
-
Carbonic Anhydrase Inhibitors / pharmacology*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / metabolism
-
Carcinoma, Renal Cell / pathology
-
Cell Proliferation / drug effects
-
Drug Screening Assays, Antitumor
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / metabolism
-
Kidney Neoplasms / pathology
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / metabolism
-
Neoplasms, Experimental / pathology
-
Small Molecule Libraries / chemistry
-
Small Molecule Libraries / pharmacology*
-
Tumor Hypoxia / drug effects*
Substances
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
Antineoplastic Agents
-
Carbonic Anhydrase Inhibitors
-
Small Molecule Libraries
-
CA9 protein, human
-
Carbonic Anhydrase IX